Publikationen in Zusammenarbeit mit Forschern von Instituto Valenciano de Oncologia (29)

2024

  1. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 35, Núm. 3, pp. 248-266

  2. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2023

  1. A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer

    Frontiers in Immunology, Vol. 14

  2. ASO Visual Abstract: Accuracy and Survival Outcomes After National Implementation of Sentinel Lymph Node Biopsy in Early-Stage Endometrial Cancer

    Annals of surgical oncology, Vol. 30, Núm. 12, pp. 7669-7670

  3. Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer

    Annals of Surgical Oncology, Vol. 30, Núm. 12, pp. 7653-7662

  4. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients

    Journal of Translational Medicine, Vol. 21, Núm. 1

  5. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: Multicenter, phase Ib dose escalation and expansion study

    International Journal of Gynecological Cancer, Vol. 33, Núm. 4, pp. 562-570

  6. The Scarface Score: Deciphering Response to DNA Damage Agents in High-Grade Serous Ovarian Cancer—A GEICO Study

    Cancers, Vol. 15, Núm. 11

2022

  1. Laboratory Cross-Comparison and Ring Test Trial for Tumor BRCA Testing in a Multicenter Epithelial Ovarian Cancer Series: The BORNEO GEICO 60-0 Study

    Journal of Personalized Medicine, Vol. 12, Núm. 11

  2. Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study

    Cancers, Vol. 14, Núm. 4

  3. Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network

    Cancers, Vol. 14, Núm. 8

2021

  1. Management of advanced ovarian cancer in Spain: an expert Delphi consensus

    Journal of Ovarian Research, Vol. 14, Núm. 1

2019

  1. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy

    European Journal of Cancer, Vol. 117, pp. 99-106

  2. Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer

    Anti-Cancer Drugs, Vol. 30, Núm. 6, pp. 628-635

  3. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study

    Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789

2018

  1. Erratum to: Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology (Clinical and Translational Oncology, (2018), 20, 3, (274-285), 10.1007/s12094-017-1719-x)

    Clinical and Translational Oncology

  2. OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

    Annals of Oncology, Vol. 29, Núm. 2, pp. 431-438

  3. OV21/PETROC: A randomized gynecologic cancer intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

    Obstetrical and Gynecological Survey

  4. Recommendations for biomarker testing in epithelial ovarian cancer. A national consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia

  5. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 20, Núm. 3, pp. 274-285